Evidence map›Paper›PMID 33227392›Full record

ArticleThe international journal of biochemistry & cell biology2021

TNFAIP8 drives metabolic reprogramming to promote prostate cancer cell proliferation.

Suryakant Niture, Minghui Lin, Joab O Odera, John Moore, Hong Zhe, Xiaoxin Chen, Simeng Suy, Sean P Collins, Deepak Kumar

Open access · greenAbstract read
In one paragraph

Article in The international journal of biochemistry & cell biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Suryakant NitureJulius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University Durham, NC 27707, USA.
Minghui LinNingxia Medical University, Yinchuan, Ningxia, 750004, China.
Joab O OderaJulius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University Durham, NC 27707, USA.
John MooreJulius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University Durham, NC 27707, USA.
Hong ZheDepartment of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004 China.
Xiaoxin ChenJulius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University Durham, NC 27707, USA.
Simeng SuyDepartment of Radiation Medicine, Georgetown University Hospital, WA, DC 20057, USA.
Sean P CollinsDepartment of Radiation Medicine, Georgetown University Hospital, WA, DC 20057, USA.
Deepak KumarJulius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University Durham, NC 27707, USA. Electronic address: dkumar@nccu.edu.
North Carolina Central University · USGeorgetown University · USNingxia Medical University · CN

Funding

Understanding Perceptions of HIV Risk, PrEP, and PrEP use among African American Women Attending an HBCUU54MD012392 · NIMHD · NORTH CAROLINA CENTRAL UNIVERSITY · PI Seronda A Robinson · 2017 to 2026
$38.1M
Molecular Determinants of Social Factors in Prostate CancerR01MD012767 · NIMHD · NORTH CAROLINA CENTRAL UNIVERSITY · PI KUMAR, DEEPAK · 2017 to 2021
$5.7M
MicroRNAs in African American Prostate CancerU01CA194730 · NCI · UNIVERSITY OF THE DISTRICT OF COLUMBIA · PI KUMAR, DEEPAK · 2015 to 2020
$1.8M
NCI NIH HHS U01 CA194730NIMHD NIH HHS R01 MD012767NIMHD NIH HHS U54 MD012392
6 · The paper itself

Abstract

Tumor necrosis factor-α-induced protein 8 (TNFAIP8) is a member of TIPE/TNFAIP8 family, has been involved in the development and progression of various human cancers. We hypothesized that TNFAIP8 promotes prostate cancer (PCa) progression via regulation of oxidative phosphorylation (OXPHOS) and glycolysis. Ectopic expression of TNFAIP8 increased PCa cell proliferation/migration/spheroid formation by enhancing cell metabolic activities. Mechanistically, TNFAIP8 activated the PI3K-AKT pathway and up-regulated PCa cell survival. TNFAIP8 was also found to regulate the expression of glucose metabolizing enzymes, enhancing glucose consumption, and endogenous ATP production. Treatment with a glycolysis inhibitor, 2-deoxyglucose (2-DG), reduced TNFAIP8 mediated glucose consumption, ATP production, spheroid formation, and PCa cell migration. By maintaining mitochondrial membrane potential, TNFAIP8 increased OXPHOS and glycolysis. Moreover, TNFAIP8 modulates the production of glycolytic metabolites in PCa cells. Collectively, our data suggest that TNFAIP8 exerts its oncogenic effects by enhancing glucose metabolism and by facilitating metabolic reprogramming in PCa cells. Therefore, TNFAIP8 may be a biomarker associated with prostate cancer and indicate a potential therapeutic target.

Indexed as

Apoptosis Regulatory ProteinsCell Line, TumorCell MovementCell ProliferationGlycolysisHumansMaleMetabolismOxidative PhosphorylationProstatic NeoplasmsSignal TransductionApoptosis Regulatory ProteinsTNFAIP8 protein, humanCell survivalGlycolysisMetabolic reprogrammingOXPHOSPI3K-AKT pathwayProstate cancerTumor necrosis factor-α-induced protein 8 (TNFAIP8)

Identifiers

PMID33227392
PMCPMC7770075
OpenAlexW3103402648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.